'RevoAb™', A New Service for Antibody Developability Engineering

RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProteinยฎ is pleased to announce the launch of a new contract research service, 'RevoAbโ„ข'. This service engineers antibodies to improve physicochemical properties while protecting antigen binding affinity.

About RevoAbโ„ข

Since December 2023, RevolKa has offered contract research services for antibody engineering using aiProteinยฎ, its AI-driven protein engineering technology, through FUJIFILM Wako Pure Chemical Corporation in Japan.

RevoAbโ„ข is a new online service for antibody developability engineering based on "RevolKa's Refined Naturalness Design concept," This refines antibody framework sequences to be close to those in naturally occurring antibodies. The pilot version was released in Japan in July 2025. Based on customer feedback, we are now launching an upgraded RevoAbโ„ข world-wide.

With RevoAbโ„ข, users can instantly access multiple antibody sequences with potential improvement in properties, such as expression levels, stability, solubility, etc., at low prices.

For more details, please visit.:

https://revoab.revolka.com/en/

Story behind RevoAbโ„ข Development.

Antibodies are proteins that provide immune protection by recognizing and binding to substances (antigens) from infecting bacteria and viruses. They are widely used in industries, such as therapeutics and diagnostics. However, antibodies are often fragile for industrial applications, and enhancing their properties typically requires significant time and resources.

RevolKa has successfully engineered many proteins using aiProteinยฎ in collaboration with customers. For antibodies, we identified that part of aiProteinยฎ could become a valuable tool for scientists struggling with suboptimal physicochemical properties. It is engineering of framework sequences of antibody by using RevolKa's Refined Naturalness Design concept. We developed RevoAbโ„ข to provide research scientists with โ€œWinning Antibody Sequencesโ€ instantly online.

Fees

Target

Origins

Price per target

Remarks

Fragment of variable regions(Fv)

Human

Rabbit

Mouse

Rat

USD700

One target: one heavy chain sequence + one light chain sequence.

ย 

Humanized Fv considered as human.

Others

USD350

Variable heavy domain of heavy chain(VHH)

Camelids

USD350

Humanized VHH not supported.

Registration

Please review and agree to the terms of use and privacy policy before filling out the form on the landing page.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.77
-0.80 (-0.38%)
AAPL  255.92
+0.29 (0.11%)
AMD  217.50
+7.29 (3.47%)
BAC  49.38
+0.11 (0.22%)
GOOG  294.46
-0.44 (-0.15%)
META  574.46
-4.77 (-0.82%)
MSFT  373.46
+4.09 (1.11%)
NVDA  177.39
+1.64 (0.93%)
ORCL  146.38
+1.15 (0.79%)
TSLA  360.59
-20.67 (-5.42%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Gift this article